Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

L Annemans, V Rémy, J Oyee, N Largeron - Pharmacoeconomics, 2009 - Springer
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …
被引用次数：48 相关文章

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium

L Annemans, V Rémy, J Oyee… - …, 2009 - econpapers.repec.org
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

L Annemans, V Remy, J Oyee, N Largeron - PharmacoEconomics, 2009 - go.gale.com
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium

L Annemans, V Rémy, J Oyee… - …, 2009 - search.proquest.com
The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine
is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial …

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium.

L Annemans, V Rémy, J Oyee… - …, 2009 - search.ebscohost.com
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

L Annemans, V Rémy, J Oyee, N Largeron - Pharmacoeconomics, 2009 - europepmc.org
Background The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

L Annemans, V Remy, J Oyee, N Largeron - Pharmacoeconomics, 2009 - lib.ugent.be
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

L Annemans, V Rémy, J Oyee… - …, 2009 - pubmed.ncbi.nlm.nih.gov
Background The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

L Annemans, V Remy, J Oyee, N Largeron - Pharmacoeconomics, 2009 - biblio.ugent.be
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium

L Annemans, V Rémy, J Oyee, N Largeron - PharmacoEconomics, 2009 - ideas.repec.org
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …